Spirea completes seed funding round to develop next gen of antibody drug conjugate therapeutics

Spirea Limited (Spirea), a spin-out from the University of Cambridge founded to deliver the next generation of antibody drug conjugate (ADC) therapeutics for the treatment of multiple cancers, has closed a seed investment round, led by Meltwind and Start Codon.

The financing will progress the development of its ADC technology, which allows the delivery of more drug payload to tumour cells resulting in greater efficacy, tolerability and the ability to treat more cancer patients.

ADC drugs combine the cell killing activity of a cytotoxic drug payload with the targeting ability of an antibody. Despite strong interest in the field from pharmaceutical companies, only eight ADCs have successfully reached the market with many programmes stalled due to constraints with the format, toxic side-effects and limitations in the range of cancer patients who can be treated.

Spirea’s novel technology overcomes these issues by offering high drug-to-antibody ratios (DAR), drug stability and design flexibility which enable the development of differentiated ADCs with improved efficacy and safety. Because the technology allows more drug to be loaded onto the targeting antibody whilst maintaining drug stability, payloads can also be customised to the target, enabling flexibility in payload potencies, creative drug combinations and novel modes of action to serve a wider patient group.

Recent in vitro proof-of-concept studies have demonstrated successful ADC manufacturing with an impressive DAR, no aggregation, good serum stability and high cell-killing activity on HER2 breast cancer cells.

Dr Myriam Ouberai, CEO of Spirea, said: “Incorporation of our technology into ADC products will accelerate and energise the important transition away from the ‘one size fits all’ approach currently being pursued in ADC development, resulting in novel products with a competitive and differentiated profile.

“The platform has the power to unlock the development of a new generation of powerful and well-tolerated drugs, which have been so far inaccessible to many cancer patients. We are delighted to have attracted seed funding from Meltwind and Start Codon, and to be part of the first Start Codon incubator programme.

“This investment and support serve as endorsements of our approach and will allow us to optimise and validate our technology.”

Dr Jonathan Milner, Executive Director at Meltwind, said: “The market for ADCs is anticipated to reach $7.5 billion by 2025. Spirea’s transformative approach to addressing the common obstacles faced in ADC development has the potential to disrupt this field entirely, placing the Company in a unique position to address a very significant market opportunity. This is an exciting time for Spirea and we are pleased to be supporting them.”

Dr Jason Mellad, Co-Founder and CEO at Start Codon, said: “We are very excited to be working closely with Spirea to support their start-up journey. The company has already demonstrated promising in vitro results and we look forward to seeing the technology develop further.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Related news

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...